Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11198442 | 0.81 | TDP1 (0.39) | LMNATDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7753131 | 0.78 | MEN1 (0.46) | POLBKMT2AHTTALDH1A1HSD17B10 | |
| SCHEMBL7099438 | 0.74 | KDM4E (0.48) | LMNAPOLBKMT2AHTTHTR3A | |
| SCHEMBL8020018 | 0.74 | ADRA2B (0.41) | LMNACYP2C19POLBKMT2AHTT | |
| SCHEMBL6977056 | 0.74 | SIRT6 (0.44) | LMNAPOLBKMT2AADRB1ALDH1A1 | |
| SCHEMBL15453937 | 0.73 | ARG1 (0.35) | — | |
| SCHEMBL6072900 | 0.72 | NPC1 (0.43) | LMNACYP3A4PTGS2KMT2AALDH1A1 | |
| SCHEMBL10631363 | 0.72 | ADRA2A (0.40) | LMNACYP2C9CYP2C19CYP2D6KMT2A | |
| Acetic Acid SCHEMBL6967868 | 0.71 | GAA (0.43) | LMNAPOLBKMT2AHTTALDH1A1 | |
| SCHEMBL8304928 | 0.71 | ADRA2A (0.48) | CYP3A4IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112472715-B | Sodium bicarbonate enteric capsule and preparation method thereof | 华熙生物科技股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-112472715-A | Sodium bicarbonate enteric-coated capsule and preparation method thereof | 华熙生物科技股份有限公司 | 2021-03-12 | — | — | CN | claimed |
| EP-2276472-B1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | ADARE PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | claimed |
| CN-104874021-A | Method for preparing forging bone for surgical implantation | BEIJING AOSITESAI MEDICAL TECHNOLOGY CO LTD | 2015-09-02 | — | — | CN | claimed |
| CN-102006862-A | Compositions and controlled release dosage forms comprising weakly basic drugs | EURAND INC | 2011-04-06 | — | — | CN | claimed |
| EP-2276472-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | Eurand, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| US-20100239563-A1 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES | LUDWIG STEPHAN | 2010-09-23 | — | — | US | claimed |
| WO-2009129282-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | EURAND INC (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090258066-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | ADARE PHARMACEUTICALS USA, INC. | 2009-10-15 | — | — | US | claimed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | claimed |
| EP-1707193-A2 | Pharmaceutical composition for the prophylaxis and/or treatment of viral diseases | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2006-10-04 | — | — | EP | claimed |
| EP-1617858-A2 | USE OF ACTIVE INGREDIENTS FOR PREVENTING OR TREATING VIRAL ILLNESSES, AND TEST SYSTEM FOR DISCOVERING SUCH ACTIVE INGREDIENTS | InAmed GmbH Institut für Aerosol Medizin (DE) | 2006-01-25 | — | — | EP | claimed |
| US-20050129694-A1 | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | LUDWIG STEPHAN (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2004085682-A2 | CASPASE INHIBITORS, ESPECIALLY CASPASE 3 INHIBITORS, FOR THE TREATMENT OF INFLUENZA | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2004-10-07 | — | — | WO | claimed |
| EP-1450778-A2 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRUS DISEASES | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | claimed |
| WO-2003015689-A2 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRUS DISEASES | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2003-02-27 | — | — | WO | claimed |
| WO-2002089779-A2 | COMBINED PREPARATION FOR THE PROPHYLAXIS AND/OR THERAPY OF NERVE CELL AND/OR GLIA CELL DAMAGE USING A NOVEL METHOD OF TREATMENT | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2002-11-14 | — | — | WO | claimed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | claimed |
| CN-1180311-A | Use of 'alpha' 1L agonists in treatment of incontinence | BOEHRINGER INGELHEIM KG (DE) | 1998-04-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | LMNA 2576/4885TDP1 2969/4885CYP1A2 2323/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | LMNA 818/4885TDP1 963/4885CYP1A2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.